Last reviewed · How we verify
NCT05236582
Herombopag for Chemotherapy-induced Thrombocytopenia
Phase 2 trial testing Herombopag in Chemotherapy-induced Thrombocytopenia in 50 participants. Currently enrolling.
31 December 2024
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 14 March 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Herombopag — full drug profile →
Conditions studied
- Chemotherapy-induced Thrombocytopenia — all drugs for Chemotherapy-induced Thrombocytopenia →
- Herombopag — all drugs for Herombopag →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
18 and older, any sex, with Chemotherapy-induced Thrombocytopenia or Herombopag. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05236582
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Herombopag
Trials testing the same drug.
- NCT07198672 — Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag · NA · not yet recruiting
- NCT05685420 — Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia · Phase 3 · unknown
- NCT05660785 — Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia · Phase 2 · completed
- NCT05328804 — Herombopag + rhTPO in Severe Immune Thrombocytopenia · Phase 3 · unknown
Other recruiting trials for Chemotherapy-induced Thrombocytopenia
Currently open trials in the same condition.
- NCT05218226 — Avatrombopag for Chemotherapy-induced Thrombocytopenia · Phase 2 · recruiting
- NCT04600960 — Eltrombopag for Chemotherapy-induced Thrombocytopenia · Phase 2 · recruiting
- NCT03937154 — Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) · Phase 3 · active not recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05236582 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 24 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05236582.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing